FDA re­view de­tails sui­cides, car­dio risks linked to Valeant’s $100M drug bro­dalum­ab

At one point not long ago, As­traZeneca ex­ecs thought their IL-17 pso­ri­a­sis drug bro­dalum­ab could earn up to $1.5 bil­lion in an­nu­al sales. But af­ter Phase III, they of­floaded it to Valeant for $100 mil­lion up­front plus mile­stones. And brief­ing doc­u­ments filed by FDA in­sid­ers spell out the se­ri­ous prob­lem with sui­cides and sui­ci­dal think­ing that caused both As­traZeneca and its part­ner Am­gen to aban­don the drug near the end of their ex­ten­sive late-stage pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER